Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 18, 2016. The document serves as a transaction notification regarding a Person Closely Associated (PCA) with a Principal Director, Manager, or Representative (PDMR).
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It is a regulatory disclosure of a specific share transaction rather than a financial performance report.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of Ordinary Shares |
| Instrument | Ordinary Shares of 25 pence each (ISIN: GB0009252882) |
| Price per Share | £16.5875 |
| Volume | 1,926 shares |
| Transaction Date | July 14, 2016 |
| Exchange | London Stock Exchange (XLON) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a single transaction involving the re-investment of dividends paid to shareholders on July 14, 2016, by Lady C Witty, a PCA of Sir Andrew Witty (CEO).
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is strictly a notification of a share acquisition event.
Key Facts for Investor Verification
- The transaction was an acquisition of 1,926 ordinary shares at £16.5875 per share.
- The purchase was executed via dividend re-investment on July 14, 2016.
- The transaction involved Lady C Witty, identified as a PCA of the CEO, Sir Andrew Witty.
- The filing does not disclose any broader financial results or strategic updates for the period.